Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7293   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-001092-39
    Sponsor's Protocol Code Number:CAQW051A2209
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-06-20
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2011-001092-39
    A.3Full title of the trial
    A multi-centre, randomized, double-blind, placebo-controlled, parallelgroup, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson's patients with moderate to severe L-dopa induced dyskinesias
    Studio multicentrico, randomizzato, in doppio cieco, controllato verso placebo, a gruppi paralleli, con dose orale multipla per valutare l efficacia, la sicurezza e la tollerabilita' di AQW051 nella riduzione delle discinesie indotte da L-dopa in pazienti affetti da malattia di Parkinson con discinesie indotte da L-dopa da moderate a severe
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson's patients with moderate to severe L-dopa induced dyskinesias
    l’efficacia, la sicurezza e la tollerabilita' di AQW051 nella riduzione delle discinesie indotte da L-dopa in pazienti affetti da malattia di Parkinson con discinesie indotte da L-dopa da moderate a severe
    A.4.1Sponsor's protocol code numberCAQW051A2209
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNOVARTIS FARMA
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovartis Farma
    B.5.2Functional name of contact pointDrug Regulatory Affairs
    B.5.3 Address:
    B.5.3.1Street AddressLargo Umberto Boccioni, 1
    B.5.3.2Town/ cityOriggio
    B.5.3.3Post code21040
    B.5.3.4CountryItaly
    B.5.4Telephone number+39 02 96541
    B.5.5Fax number+39 02 9659066
    B.5.6E-mailinfo.studiclinici@novartis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code AQW051
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 669770-29-0
    D.3.9.2Current sponsor codeAQW051
    D.3.9.3Other descriptive nameNot established
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code AQW051
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 669770-29-0
    D.3.9.2Current sponsor codeAQW051
    D.3.9.3Other descriptive nameNot established
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    L-dopa induced dyskinesias in Parkinson's patients
    pazienti con malattia di Parkinson con discinesie indotte dalla L-dopa
    E.1.1.1Medical condition in easily understood language
    dyskinesias (Abnormal Involuntary Movement) in Parkinson's patients
    pazienti con malattia di Parkinson con discinesie (Movimento involontario anormale)
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level HLT
    E.1.2Classification code 10013929
    E.1.2Term Dyskinesias and movement disorders NEC
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10013113
    E.1.2Term Disease Parkinson's
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    • To assess the anti-dyskinetic efficacy of multiple doses of AQW051 in Parkinson's patients with moderate to severe L-dopa induced dyskinesias using the modified Abnormal Involuntary Movement Scale (mAIMS). • To assess the anti-parkinsonian effect of multiple doses of AQW051 in combination with L-dopa in Parkinson's patients with moderate to severe L-dopa induced dyskinesias using the Unified Parkinson's Disease Rating Scale (UPDRS) – part III. • To assess the safety and tolerability of multiple doses of AQW051 in combination with Ldopa in Parkinson's patients with moderate to severe L-dopa induced dyskinesias.
    Valutare l’efficacia anti-discinetica di dosi multiple di AQW051 in pazienti affetti da malattia di Parkinson con discinesie indotte da L-dopa da moderate a severe utilizzando la scala modified Abnormal Involuntary Movement Scale (mAIMS).  Valutare l’effetto anti-parkinsoniano di dosi multiple di AQW051 in combinazione con L-dopa in pazienti affetti da malattia di Parkinson con discinesie indotte da L-dopa da moderate a severe utilizzando la scala Unified Parkinson’s Disease Rating Scale (UPDRS) – parte III.  Valutare la sicurezza e tollerabilita' di dosi multiple di AWQ051 in combinazione con L-dopa in pazienti affetti da malattia di Parkinson con discinesie indotte da L-dopa da moderate a severe
    E.2.2Secondary objectives of the trial
    • To assess the anti-dyskinetic efficacy of multiple doses of AQW051 in Parkinson's patients with moderate to severe L-dopa induced dyskinesias using the Lang-Fahn Activities of Daily Living Dyskinesia Scale (LFADLDS) and UPDRS(32-33). • To assess the anti-dyskinetic efficacy of multiple doses of AQW051 on Track-PD assessments in Parkinson's patients with moderate to severe L-dopa induced dyskinesias. • To assess the cognitive effects of multiple doses of AQW051 in Parkinson's patients with moderate to severe L-dopa induced dyskinesias. • To measure the pharmacokinetics of multiple doses of AQW051 in Parkinson's patients.
    Valutare l’efficacia anti-discinetica di dosi multiple di AQW051 in pazienti affetti da malattia di Parkinson con discinesie indotte da L-dopa da moderate a severe utilizzando le scale Lang-Fahn Activities of Daily Living Dyskinesia Scale (LFADLDS) e UPDRS. Valutare l’efficacia anti-discinetica di dosi multiple di AQW051 sulle valutazioni Track-PD in pazienti affetti da malattia di Parkinson con discinesie indotte da L-dopa da moderate a severe.Valutare gli effetti sulle funzioni cognitive di dosi multiple di AQW051 in pazienti affetti da Parkinson con discinesie indotte da L-dopa da moderate a severe. Misurare la farmacocinetica di dosi multiple di AQW051 in pazienti affetti da malattia di Parkinson.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    PHARMACOGENETIC:
    Vers:02
    Date:2011/11/21
    Title:N.A.
    Objectives:Pharmacogenetics Exploratory pharmacogenetics research studies are planned as a part of this study

    PHARMACOGENOMIC:
    Vers:02
    Date:2011/11/21
    Title:N.A.
    Objectives:Exploratory pharmacogenomics research studies are planned as a part of this study

    PHARMACOKINETIC/PHARMACODYNAMIC:
    Vers:02
    Date:2011/11/21
    Title:N.A.
    Objectives:Pharmacokinetics Plasma samples will be obtained to determine AQW051 pharmacokinetics. Leftover samples may be used for analyses relating to metabolites of AQW051. See Sample log tables (Appendix 1-Section 13).

    FARMACOGENETICA:
    Vers:02
    Data:2011/11/21
    Titolo:(N.A.) Anche se il protocollo non prevede sottostudi formalmente definiti (ovvero strutturati con un protocollo specifico) ma indagini complementari opzionali, le stesse vengono classificate come sottostudi. Di seguito il dettaglio: • Indagine sui marcatori biologici (farmacogenetica, farmacogenomica e indicatori biologici neurodegenerativi e infiammatori nel fluido cerebrospinale), a cui possono partecipare tutti i centri italiani coinvolti nello studio. L’eventuale non accettazione di tale sottostudio o di parte di esso da parte del Comitato Etico e/o da parte del paziente non compromettera' in alcun modo la partecipazione allo studio principale.
    Obiettivi:Farmacogenetica Gli studi esplorativi di ricerca in farmacogenetica sono progettati come una parte di questo studio

    FARMACOGENOMICA:
    Vers:02
    Data:2011/11/21
    Titolo:N.A.
    Obiettivi:Gli studi esplorativi di ricerca in farmacogenenomica sono progettati come una parte di questo studio

    FARMACOCINETICA/FARMACODINAMICA:
    Vers:02
    Data:2011/11/21
    Titolo:N.A.
    Obiettivi:Farmacocinetica I campioni del plasma saranno ottenuti per determinare la farmacocinetica di AQW051. I campioni rimanenti possono essere utilizzati per le analisi per quanto riguarda i metaboliti di AQW051. Per favore, vedere(Appendice 1-Section 13).

    E.3Principal inclusion criteria
    1. Male and female, non-smoking patients between 30 and 85 years of age (both inclusive). 2. Written informed consent must be obtained before any assessment is XML File Identifier: VXYjImYpNkc8H5t03PaNfKGLF34= Page 14/27 performed. 3. Patients with idiopathic Parkinson's disease diagnosed by UK Parkinson's disease Society Brain Bank criteria. 4. Patients with L-dopa induced dyskinesia greater than 20% (UPDRS item of 32, rating ≥1) of moderate to severe (complete disabling) intensity (UPDRS item 33 rating ≥ 2). 5. Patients with dyskinesias for at least 3 months before randomization. 6. Patients have to be on L-dopa treatment for at least 3 years prior to randomization and the L-dopa treatment has to be stable for at least 1 month prior to randomization (i.e. the total daily dose and dosing regimen can vary among patients but has to be the stable for individual patients). Other concomitant anti-parkinsonian medication (e.g. pramipexole, cabergoline, ropinirole) is allowed but the total daily dose and dosing regimen has to be stable for at least one month prior to randomization. 7. Patients treated with amantadine, antidepressants, and/or benzodiazepines are allowed to enter the study provided that they are on a stable regimen for at least 4 weeks prior to randomization. 8. Other than related to Parkinson's disease, patients must be in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and routine laboratory tests (hematology, biochemistry, urinalysis) at screening and baseline 9. Patients must weigh at least 45 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 32 kg/m2. See Appendix 3 of this protocol for BMI ranges. 10. Able to communicate well with the investigator, to understand and comply with the requirements of the study.
    Soggetti di sesso maschile e femminile, con diagnosi di malattia di Parkinson idiopatica, di eta' compresa tra i 30 e gli 85 anni (estremi inclusi)  Pazienti con discinesie indotte da L-dopa superiori al 20% e di intensita' da moderata a severa  Pazienti con discinesie da almeno 3 mesi prima della randomizzazione  Pazienti in trattamento con L-dopa da almeno 3 anni prima della randomizzazione  Soggetti con peso corporeo di almeno 45 kg, indice di massa corporea (Body Mass Index – BMI) compreso tra 18 e 32 kg/m2
    E.4Principal exclusion criteria
    Parkinson's disease related: 1. Patients with a prior surgery for Parkinson's disease (e.g. pallidotomy). 2. Patients with a Hoehn and Yahr score of 5 when 'off'. 3. Patients with atypical Parkinson's disease (Progressive Supranuclear Palsy (PSP), Multi Systemic Atrophy (MSA). 4. Patients who are under deep brain stimulation. 5. Patients with cognitive impairment (MMSE score of less than 24). 6. Patients with a presence of psychosis, confusional states and/or repeated hallucinations. 7. Patients who participated in an anti-dyskinetic clinical study in which drugs were administered within 3 months prior to randomization, or longer if required by local regulations, and any other limit on participation based on local regulations. 8. Patients who received neuroleptics or antipsychotics during 2 months before randomization. General: 9. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives of enrollment, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations. 10. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. 11. History of seizures. 12. Patients using (or have used within 5 half-lives prior to first treatment with AQW051) concomitant medication that are strong inhibitors of CYP3A4 and CYP1A2 13. A history or presence of clinically significant ECG abnormalities at Screening or Baseline. 14. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. 15. Pregnant or nursing (lactating) women. 16. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use effective contraception during the study. Please see protocol for further details. 17. Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will be measured during screening and at baseline for all subjects. Smokers will be defined as any subject who reports tobacco use and/or who has a urine cotinine ≥ 500 ng/mL. 18. Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation. 19. Significant illness within two (2) weeks prior to initial dosing. 20. Recent (within the last three [3] years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc). 21. Recent (within the last three [3] years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated). 22. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. The Investigator should make this determination in consideration of the subject's medical history and/or clinical or laboratory evidence. 23. History or presence of impaired renal function as indicated by clinically significantly abnormal creatinine or BUN and/or urea values, or abnormal urinary constituents (e.g., albuminuria). 24. Evidence of urinary obstruction or difficulty in voiding at screening. 25. History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result. 26. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. 27. History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during screening or baseline.
    Precedente intervento chirurgico per malattia di Parkinson o malattia di Parkinson atipica  Pazienti con deterioramento cognitivo (MMSE inferiore a 24)  Pazienti con presenza di psicosi, stati confusionali e/o allucinazioni ripetute  Uso di qualsiasi trattamento anti-discinetico  Anamnesi o presenza di anormalita' clinicamente significative dell’ECG allo screening o alla prima visita basale  Anamnesi o presenza di patologia maligna di qualsiasi organo  Qualsiasi condizione medica o chirurgica che potrebbe alterare in modo significativo l’assorbimento, la distribuzione, il metabolismo o l’escrezione dei farmaci  Attuali fumatori  Uso di droghe o abuso di alcol attuale o pregresso Per maggiori dettagli consultare i paragrafi 4.1 e 4.2 del protocollo originale.
    E.5 End points
    E.5.1Primary end point(s)
    mAIMs and UPDRS score
    mAIMs e UPDRS punteggio
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day 28
    Giorno 28
    E.5.2Secondary end point(s)
    LFADLDS score
    LFADLDS punteggio
    E.5.2.1Timepoint(s) of evaluation of this end point
    Day 28
    Giorno 28
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    - Stesso farmaco ad altro dosaggio
    - same IMP used at different dosage
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA16
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last visit last subject : 15/OCT/2012
    LVLS : 15/10/2012
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months13
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 36
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 36
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 51
    F.4.2.2In the whole clinical trial 72
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Each subject will be required to complete the study in its entirety and thereafter no further study treatment will be made available to them. The investigator must provide follow-up medical care for all patients who are prematurely withdrawn from the study, or must refer them for appropriate ongoing care.
    Ad ogni soggetto sara' richiesto di terminare lo studio nella sua totalita' e da allora in poi nessun ulteriore trattamento in studio e' previsto. Il ricercatore deve fornire l'assistenza medica necessaria per tutti i pazienti prematuramente ritirati dallo studio, o comunque deve essere di riferimento per i pazienti per la cura medica appropriata.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-04-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-04-19
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 07 22:24:13 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA